Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22.715
Filtrar
5.
BMC Bioinformatics ; 25(1): 118, 2024 Mar 18.
Artigo em Inglês | MEDLINE | ID: mdl-38500025

RESUMO

Bacteria in the human body, particularly in the large intestine, are known to be associated with various diseases. To identify disease-associated bacteria (markers), a typical method is to statistically compare the relative abundance of bacteria between healthy subjects and diseased patients. However, since bacteria do not necessarily cause diseases in isolation, it is also important to focus on the interactions and relationships among bacteria when examining their association with diseases. In fact, although there are common approaches to represent and analyze bacterial interaction relationships as networks, there are limited methods to find bacteria associated with diseases through network-driven analysis. In this paper, we focus on rewiring of the bacterial network and propose a new method for quantifying the rewiring. We then apply the proposed method to a group of colorectal cancer patients. We show that it can identify and detect bacteria that cannot be detected by conventional methods such as abundance comparison. Furthermore, the proposed method is implemented as a general-purpose tool and made available to the general public.


Assuntos
Bactérias , Doença , Humanos , Bactérias/patogenicidade
6.
Science ; 383(6685): 809, 2024 Feb 23.
Artigo em Inglês | MEDLINE | ID: mdl-38386750

RESUMO

All of Us finds new DNA variants and refines genetic risk scores in diverse groups.


Assuntos
Doença , Genoma Humano , Projeto Genoma Humano , Humanos , Variação Genética , National Institutes of Health (U.S.) , Doença/genética , Risco
8.
J Med Philos ; 49(2): 128-146, 2024 Mar 14.
Artigo em Inglês | MEDLINE | ID: mdl-38418083

RESUMO

Elselijn Kingma argues that Christopher Boorse's biostatistical theory (the BST) does not show how the reference classes it uses are objective and naturalistic. Recently, philosophers of medicine have attempted to rebut Kingma's concerns. I argue that these rebuttals are theoretically unconvincing, and that there are clear examples of physicians adjusting their reference classes according to their prior knowledge of health and disease. I focus on the use of age-adjusted reference classes to diagnose low bone mineral density in children. In addition to using the BST's age, sex, and species, physicians also choose to use other factors to define reference classes, such as pubertal status, bone age, body size, and muscle mass. I show that physicians calibrate the reference classes they use according to their prior knowledge of health and disease. Reference classes are also chosen for pragmatic reasons, such as to predict fragility fractures.


Assuntos
Doenças Ósseas Metabólicas , Doença , Medicina , Criança , Humanos , Saúde , Filosofia Médica
10.
J Cell Physiol ; 239(3): e31194, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38230572
11.
Nature ; 626(8000): 897-904, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38297118

RESUMO

Intrinsically disordered proteins and regions (collectively, IDRs) are pervasive across proteomes in all kingdoms of life, help to shape biological functions and are involved in numerous diseases. IDRs populate a diverse set of transiently formed structures and defy conventional sequence-structure-function relationships1. Developments in protein science have made it possible to predict the three-dimensional structures of folded proteins at the proteome scale2. By contrast, there is a lack of knowledge about the conformational properties of IDRs, partly because the sequences of disordered proteins are poorly conserved and also because only a few of these proteins have been characterized experimentally. The inability to predict structural properties of IDRs across the proteome has limited our understanding of the functional roles of IDRs and how evolution shapes them. As a supplement to previous structural studies of individual IDRs3, we developed an efficient molecular model to generate conformational ensembles of IDRs and thereby to predict their conformational properties from sequences4,5. Here we use this model to simulate nearly all of the IDRs in the human proteome. Examining conformational ensembles of 28,058 IDRs, we show how chain compaction is correlated with cellular function and localization. We provide insights into how sequence features relate to chain compaction and, using a machine-learning model trained on our simulation data, show the conservation of conformational properties across orthologues. Our results recapitulate observations from previous studies of individual protein systems and exemplify how to link-at the proteome scale-conformational ensembles with cellular function and localization, amino acid sequence, evolutionary conservation and disease variants. Our freely available database of conformational properties will encourage further experimental investigation and enable the generation of hypotheses about the biological roles and evolution of IDRs.


Assuntos
Proteínas Intrinsicamente Desordenadas , Modelos Moleculares , Conformação Proteica , Proteoma , Humanos , Sequência de Aminoácidos , Proteínas Intrinsicamente Desordenadas/química , Proteínas Intrinsicamente Desordenadas/genética , Proteínas Intrinsicamente Desordenadas/metabolismo , Proteoma/química , Proteoma/metabolismo , Relação Estrutura-Atividade , Evolução Molecular , Doença/genética
13.
Nucleic Acids Res ; 52(D1): D633-D639, 2024 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-37897362

RESUMO

Metabolite-associated cell communications play critical roles in maintaining the normal biological function of human through coordinating cells, organs and physiological systems. Though substantial information of MACCs has been continuously reported, no relevant database has become available so far. To address this gap, we here developed the first knowledgebase (MACC), to comprehensively describe human metabolite-associated cell communications through curation of experimental literatures. MACC currently contains: (a) 4206 carefully curated metabolite-associated cell communications pairs involving 244 human endogenous metabolites and reported biological effects in vivo and in vitro; (b) 226 comprehensive cell subtypes and 296 disease states, such as cancers, autoimmune diseases, and pathogenic infections; (c) 4508 metabolite-related enzymes and transporters, involving 542 pathways; (d) an interactive tool with user-friendly interface to visualize networks of multiple metabolite-cell interactions. (e) overall expression landscape of metabolite-associated gene sets derived from over 1500 single-cell expression profiles to infer metabolites variations across different cells in the sample. Also, MACC enables cross-links to well-known databases, such as HMDB, DrugBank, TTD and PubMed etc. In complement to ligand-receptor databases, MACC may give new perspectives of alternative communication between cells via metabolite secretion and adsorption, together with the resulting biological functions. MACC is publicly accessible at: http://macc.badd-cao.net/.


Assuntos
Comunicação Celular , Doença , Bases de Conhecimento , Metaboloma , Humanos
14.
Nucleic Acids Res ; 52(D1): D938-D949, 2024 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-38000386

RESUMO

Bridging the gap between genetic variations, environmental determinants, and phenotypic outcomes is critical for supporting clinical diagnosis and understanding mechanisms of diseases. It requires integrating open data at a global scale. The Monarch Initiative advances these goals by developing open ontologies, semantic data models, and knowledge graphs for translational research. The Monarch App is an integrated platform combining data about genes, phenotypes, and diseases across species. Monarch's APIs enable access to carefully curated datasets and advanced analysis tools that support the understanding and diagnosis of disease for diverse applications such as variant prioritization, deep phenotyping, and patient profile-matching. We have migrated our system into a scalable, cloud-based infrastructure; simplified Monarch's data ingestion and knowledge graph integration systems; enhanced data mapping and integration standards; and developed a new user interface with novel search and graph navigation features. Furthermore, we advanced Monarch's analytic tools by developing a customized plugin for OpenAI's ChatGPT to increase the reliability of its responses about phenotypic data, allowing us to interrogate the knowledge in the Monarch graph using state-of-the-art Large Language Models. The resources of the Monarch Initiative can be found at monarchinitiative.org and its corresponding code repository at github.com/monarch-initiative/monarch-app.


Assuntos
Bases de Dados Factuais , Doença , Genes , Fenótipo , Humanos , Internet , Bases de Dados Factuais/normas , Software , Genes/genética , Doença/genética
16.
Nucleic Acids Res ; 52(D1): D1450-D1464, 2024 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-37850638

RESUMO

Distinct from the traditional diagnostic/prognostic biomarker (adopted as the indicator of disease state/process), the therapeutic biomarker (ThMAR) has emerged to be very crucial in the clinical development and clinical practice of all therapies. There are five types of ThMAR that have been found to play indispensable roles in various stages of drug discovery, such as: Pharmacodynamic Biomarker essential for guaranteeing the pharmacological effects of a therapy, Safety Biomarker critical for assessing the extent or likelihood of therapy-induced toxicity, Monitoring Biomarker indispensable for guiding clinical management by serially measuring patients' status, Predictive Biomarker crucial for maximizing the clinical outcome of a therapy for specific individuals, and Surrogate Endpoint fundamental for accelerating the approval of a therapy. However, these data of ThMARs has not been comprehensively described by any of the existing databases. Herein, a database, named 'TheMarker', was therefore constructed to (a) systematically offer all five types of ThMAR used at different stages of drug development, (b) comprehensively describe ThMAR information for the largest number of drugs among available databases, (c) extensively cover the widest disease classes by not just focusing on anticancer therapies. These data in TheMarker are expected to have great implication and significant impact on drug discovery and clinical practice, and it is freely accessible without any login requirement at: https://idrblab.org/themarker.


Assuntos
Biomarcadores , Bases de Dados Factuais , Humanos , Descoberta de Drogas , Terapêutica , Prognóstico , Doença
17.
Nucleic Acids Res ; 52(D1): D1236-D1245, 2024 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-37930831

RESUMO

Molecular signatures are usually sets of biomolecules that can serve as diagnostic, prognostic, predictive, or therapeutic markers for a specific disease. Omics data derived from various high-throughput molecular biology technologies offer global, unbiased and appropriately comparable data, which can be used to identify such molecular signatures. To address the need for comprehensive disease signatures, DiSignAtlas (http://www.inbirg.com/disignatlas/) was developed to provide transcriptomics-based signatures for a wide range of diseases. A total of 181 434 transcriptome profiles were manually curated from studies involving 1836 nonredundant disease types in humans and mice. Then, 10 306 comparison datasets comprising both disease and control samples, including 328 single-cell RNA sequencing datasets, were established. Furthermore, a total of 3 775 317 differentially expressed genes in humans and 1 723 674 in mice were identified as disease signatures by analysing transcriptome profiles using commonly used pipelines. In addition to providing multiple methods for the retrieval of disease signatures, DiSignAtlas provides downstream functional enrichment analysis, cell type analysis and signature correlation analysis between diseases or species when available. Moreover, multiple analytical and comparison tools for disease signatures are available. DiSignAtlas is expected to become a valuable resource for both bioscientists and bioinformaticians engaged in translational research.


Assuntos
Bases de Dados Genéticas , Doença , Análise da Expressão Gênica de Célula Única , Animais , Humanos , Camundongos , Transcriptoma/genética , Doença/genética , Conjuntos de Dados como Assunto
18.
IEEE Trans Med Imaging ; 43(1): 190-202, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-37428659

RESUMO

Open set recognition (OSR) aims to accurately classify known diseases and recognize unseen diseases as the unknown class in medical scenarios. However, in existing OSR approaches, gathering data from distributed sites to construct large-scale centralized training datasets usually leads to high privacy and security risk, which could be alleviated elegantly via the popular cross-site training paradigm, federated learning (FL). To this end, we represent the first effort to formulate federated open set recognition (FedOSR), and meanwhile propose a novel Federated Open Set Synthesis (FedOSS) framework to address the core challenge of FedOSR: the unavailability of unknown samples for all anticipated clients during the training phase. The proposed FedOSS framework mainly leverages two modules, i.e., Discrete Unknown Sample Synthesis (DUSS) and Federated Open Space Sampling (FOSS), to generate virtual unknown samples for learning decision boundaries between known and unknown classes. Specifically, DUSS exploits inter-client knowledge inconsistency to recognize known samples near decision boundaries and then pushes them beyond decision boundaries to synthesize discrete virtual unknown samples. FOSS unites these generated unknown samples from different clients to estimate the class-conditional distributions of open data space near decision boundaries and further samples open data, thereby improving the diversity of virtual unknown samples. Additionally, we conduct comprehensive ablation experiments to verify the effectiveness of DUSS and FOSS. FedOSS shows superior performance on public medical datasets in comparison with state-of-the-art approaches. The source code is available at https://github.com/CityU-AIM-Group/FedOSS.


Assuntos
Aprendizado de Máquina , Software , Humanos , Doença
19.
Nucleic Acids Res ; 52(D1): D1327-D1332, 2024 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-37650649

RESUMO

MicroRNAs (miRNAs) are a class of important small non-coding RNAs with critical molecular functions in almost all biological processes, and thus, they play important roles in disease diagnosis and therapy. Human MicroRNA Disease Database (HMDD) represents an important and comprehensive resource for biomedical researchers in miRNA-related medicine. Here, we introduce HMDD v4.0, which curates 53530 miRNA-disease association entries from literatures. In comparison to HMDD v3.0 released five years ago, HMDD v4.0 contains 1.5 times more entries. In addition, some new categories have been curated, including exosomal miRNAs implicated in diseases, virus-encoded miRNAs involved in human diseases, and entries containing miRNA-circRNA interactions. We also curated sex-biased miRNAs in diseases. Furthermore, in a case study, disease similarity analysis successfully revealed that sex-biased miRNAs related to developmental anomalies are associated with a number of human diseases with sex bias. HMDD can be freely visited at http://www.cuilab.cn/hmdd.


Assuntos
Bases de Dados de Ácidos Nucleicos , Doença , MicroRNAs , Humanos , MicroRNAs/genética , Doença/genética
20.
Nucleic Acids Res ; 52(D1): D607-D621, 2024 Jan 05.
Artigo em Inglês | MEDLINE | ID: mdl-37757861

RESUMO

Liquid biopsy has emerged as a promising non-invasive approach for detecting, monitoring diseases, and predicting their recurrence. However, the effective utilization of liquid biopsy data to identify reliable biomarkers for various cancers and other diseases requires further exploration. Here, we present cfOmics, a web-accessible database (https://cfomics.ncRNAlab.org/) that integrates comprehensive multi-omics liquid biopsy data, including cfDNA, cfRNA based on next-generation sequencing, and proteome, metabolome based on mass-spectrometry data. As the first multi-omics database in the field, cfOmics encompasses a total of 17 distinct data types and 13 specimen variations across 69 disease conditions, with a collection of 11345 samples. Moreover, cfOmics includes reported potential biomarkers for reference. To facilitate effective analysis and visualization of multi-omics data, cfOmics offers powerful functionalities to its users. These functionalities include browsing, profile visualization, the Integrative Genomic Viewer, and correlation analysis, all centered around genes, microbes, or end-motifs. The primary objective of cfOmics is to assist researchers in the field of liquid biopsy by providing comprehensive multi-omics data. This enables them to explore cell-free data and extract profound insights that can significantly impact disease diagnosis, treatment monitoring, and management.


Assuntos
Biomarcadores , Bases de Dados Factuais , Doença , Multiômica , Neoplasias , Humanos , Biomarcadores/análise , Genômica/métodos , Neoplasias/química , Neoplasias/genética , Doença/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...